The Metachromatic Leukodystrophy (MLD) drugs in development market research report provides comprehensive information on the therapeutics under development for Metachromatic Leukodystrophy (MLD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Metachromatic Leukodystrophy (MLD). Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Metachromatic Leukodystrophy (MLD) and features dormant and discontinued products.
GlobalData tracks 13 drugs in development for Metachromatic Leukodystrophy (MLD) by 13 companies/universities/institutes. The top development phase for Metachromatic Leukodystrophy (MLD) is preclinical with seven drugs in that stage. The Metachromatic Leukodystrophy (MLD) pipeline has ten drugs in development by companies and three by universities/ institutes. Some of the companies in the Metachromatic Leukodystrophy (MLD) pipeline products market are: Shenzhen Second People’s Hospital, ArmaGen and JCR Pharmaceuticals.
The key targets in the Metachromatic Leukodystrophy (MLD) pipeline products market include Arylsulfatase A.
The key mechanisms of action in the Metachromatic Leukodystrophy (MLD) pipeline product include Arylsulfatase A Activator with six drugs in Phase II. The Metachromatic Leukodystrophy (MLD) pipeline products include four routes of administration with the top ROA being Intravenous and five key molecule types in the Metachromatic Leukodystrophy (MLD) pipeline products market including Gene Therapy, and Fusion Protein.
Metachromatic Leukodystrophy (MLD) overview
Metachromatic leukodystrophy (MLD) is an inherited disorder characterized by the accumulation of fats called sulfatides in cells. Symptoms include vision problems leading to blindness, personality changes, and motor disturbances such as clumsiness, muscle weakness (hypotonia), rigidity, inability to coordinate movement (ataxia), and/or muscle spasms, especially of the neck, spine, arms, and legs. Treatment for metachromatic leukodystrophy is symptomatic and supportive.
For a complete picture of Metachromatic Leukodystrophy (MLD)’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
